AST-201 (Aptamer Sciences)

N/A

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameAST-201 (Aptamer Sciences)
Drug Alias NameAST-201 Aptamer-Drug Conjugate (Aptamer Sciences)AST-201 ApDC (Aptamer Sciences)AST-201(Aptamer Sciences)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide aptamer > Raptamer-drug conjugates
Mechanisms of ActionGlypican-3 modulatorsCytidine deaminase inhibitorsDNA synthesis inhibitors
TargetsGlypican-3Cytidine deaminase
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLiver Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAptamer Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAptamer Sciences Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLiver Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A